← back to search

Mark Rosenthal

Peter MacCallum Cancer Centre ·
Area of research
Pulmonary and Respiratory Medicine · Genetics
Research interest
Research interests include Glioma Diagnosis and Treatment, Prostate Cancer Treatment and Research, Brain Metastases and Treatment, and Cancer Treatment and Pharmacology.
h-index
48
citations
15,581
works
349
NIH funding
primary concept
email

Recent publications

NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma
Neuro-Oncology Advances 2023cited by 18position: middledoi
Olutasidenib (FT-2102) in patients with relapsed or refractory <i>IDH1</i>-mutant glioma: A multicenter, open-label, phase Ib/II trial
Neuro-Oncology 2022cited by 69position: middledoi
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated<i>MGMT</i>glioblastoma: the VERTU study
Neuro-Oncology 2021cited by 86position: middledoi
A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.
Journal of Clinical Oncology 2020cited by 19position: middledoi
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Journal of Clinical Oncology 2018cited by 122position: middledoi
A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations
Blood 2016cited by 59position: middledoi
Glioma
Nature Reviews Disease Primers 2015cited by 1,143position: middledoi
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
European Urology 2015cited by 19position: middledoi
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials
Annals of Oncology 2014cited by 140position: middledoi
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Journal of Clinical Oncology 2013cited by 595position: middledoi
CLIN-ONGOING CLINICAL TRIALS
Neuro-Oncology 2012cited by 5position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Martin J. van den Bent · St James's University Hospital2 papers (2013–2016)Mario A. Eisenberger · Johns Hopkins Medicine2 papers (2014–2018) · 2 papers (2020–2022)Bertrand Tombal · UCLouvain2 papers (2014–2015)Patrick Y. Wen · Harvard University2 papers (2015–2016)Tobias Walbert · Michigan State University2 papers (2020–2022) · 2 papers (2020–2022) · 2 papers (2020–2022)Antje Wick · Heidelberg University2 papers (2013–2016) · 2 papers (2020–2022)Howard Colman · University of Utah2 papers (2020–2022)Arnoud J. Templeton · University of Basel2 papers (2014–2015)Daniel P. Petrylak · Yale Cancer Center2 papers (2015–2018)Guru Sonpavde · AdventHealth Orlando2 papers (2014–2015)Macarena I. de la Fuente · University of Miami2 papers (2020–2022)Ian F. Tannock · Princess Margaret Cancer Centre2 papers (2014–2018)Patrick Kelly · University of Maryland, College Park2 papers (2020–2022)Varun Monga · University of Iowa2 papers (2020–2022)Mohammed Milhem · Humboldt-Universität zu Berlin2 papers (2020–2022)Brian Andrew Van Tine · St. Louis Children's Hospital2 papers (2020–2022)